SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Vivos Therapeutics closed a strategic partnership with SOD Sciences, acquiring an 11% equity stake in SOD plus 50% interests in SOD's pseudohypoxia patent and the ReBalU Primed Cell Test. Payment was $12 million of Vivos Series D Convertible Preferred Stock, convertible at $0.15 per share into 80,000,000 Vivos common shares, subject to a 4.99% beneficial ownership blocker — a large potential share-count increase. The partners will split contribution margin 50/50 on every ReBalU test sold and market to more than 2,600 U.S.
Key figures
- Deal Value Usd
- 12000000
- Offering Price
- 0.15
- Shares Offered
- 80000000
- Test interest
- 50%
- Patent interest
- 50%
- Target patients
- 500000
- Sod equity stake
- 11%
- Target sleep centers
- 2600
- Beneficial ownership blocker
- 4.99%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.